CEO Corner

HUNTSVILLE, AL, July 22, 2019 – It has been a month of milestones for iCubate with our iC-GN Assay™ receiving CE IVD Marking and US FDA clearance. We look forward to talking about this and what is next for iCubate at the AACC conference in August.

iCubate now provides a comprehensive solution for bloodstream infection detection to clinical laboratories of all sizes. With assays designed to detect and identify both gram positive and gram negative organisms associated with bloodstream infection and subsequent sepsis, iCubate is proud to join the fight against this unpredictable and deadly condition. The iCubate assays also identify clinically relevant resistance markers, providing important diagnostic information that can guide in the early choice of appropriate antimicrobial therapy.

Next month at AACC in Anaheim, I invite you to stop by Booth 1692 to learn more about how iCubate can provide clinical laboratories actionable, reliable diagnostic results for improving patient care and outcomes while shortening hospital stays, reducing costs and benefiting antimicrobial stewardship programs. 

I look forward to seeing you in August.


Carter Wells
CEO, iCubate

 

About iCubate

iCubate® is a molecular diagnostic company providing accurate and affordable syndromic testing to clinical laboratories. Founded by Jian Han, MD, PhD, iCubate’s assays detect multiple pathogens concurrently with high sensitivity and specificity. The portfolio of assays are run on an integrated, intuitive, easy to use closed system. The FDA cleared and CE Marked assays deliver actionable results with improved turn-around time for pathogenic organism identification and detection of important antimicrobial resistance markers. Offering a scalable, cost-effective platform, iCubate offers accurate testing for labs of any size. To learn more about iCubate, visit iCubate.com.

 

###

 

iCubate Media Contact:

Amy Mata

amy.mata@icubate.com

256-327-9568

 

0

Post a comment